What is the current Price Target for the CSPC Pharmaceutical Group Limited stock?

The average CSPC Pharmaceutical Group Limited target price is HK$12.24. This is 37.07% higher than the current stock price. The highest price target is 127.64%, the lowest is -9.52%. 24 Analysts have issued a price target CSPC Pharmaceutical Group Limited 2027 .

How high will the CSPC Pharmaceutical Group Limited stock rise?

No reliable answer can be given as to how high the CSPC Pharmaceutical Group Limited stock will rise. The performance of stocks, including the CSPC Pharmaceutical Group Limited stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the CSPC Pharmaceutical Group Limited stock today?

The performance of CSPC Pharmaceutical Group Limited stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the CSPC Pharmaceutical Group Limited stock fall?

The decline in CSPC Pharmaceutical Group Limited stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

CSPC Pharmaceutical Group Limited Forecast, price target & analysts

HK$8.93

0.90%

Hong Kong, Sep 18, 04:00 pm HKT. Closed.

ISIN

HK1093012172

Symbol

1093

Index

Hang Seng

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Overview Dividends Analysts Charts Strategies

CSPC Pharmaceutical Group Limited Target price 2026 - Analyst rating & recommendation

CSPC Pharmaceutical Group Limited Classifications & Recommendation

Buy

79%

Hold

14%

Sell

CSPC Pharmaceutical Group Limited Price Target

Target Price	HK$12.24
Price	HK$8.93
Potential	37.07% register free of charge
Number of Estimates	24

	24 Analysts have issued a price target CSPC Pharmaceutical Group Limited 2027 . The average CSPC Pharmaceutical Group Limited target price is HK$12.24. This is 37.07% register free of charge higher than the current stock price. The highest price target is HK$20.33 127.64% register free of charge , the lowest is HK$8.08 9.52% register free of charge .
	A rating was issued by 29 analysts: 23 Analysts recommend CSPC Pharmaceutical Group Limited to buy, 4 to hold and 2 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the CSPC Pharmaceutical Group Limited stock has an average upside potential 2027 of 37.07% register free of charge . Most analysts recommend the CSPC Pharmaceutical Group Limited stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '25	2026 Estimates
Revenue Billion HK$	30.45	38.50
	10.35%	26.44%
EBITDA Margin	22.56%	35.31%
	6.12%	56.52%

25 Analysts have issued a sales forecast CSPC Pharmaceutical Group Limited 2026 . The average CSPC Pharmaceutical Group Limited sales estimate is

unlock

. This is

unlock

than the revenue of the last 12 months(TTM). The highest sales forecast is

unlock

, the lowest is

unlock

This results in the following potential growth metrics:

2025	HK$30.5b	10.35%
2026	HK$38.5b 26.44% unlock
2027	HK$36.0b 6.57% unlock
2028	HK$37.7b 4.91% unlock
2029	HK$42.9b 13.69% unlock
2030	HK$45.5b 6.15% unlock
2031	HK$48.8b 7.13% unlock
2032	HK$52.2b 6.92% unlock
2033	HK$55.6b 6.52% unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '25	2026 Estimates
Earnings Per Share HK$	0.40	0.83
	6.98%	107.50%
P/E		10.71
EV/Sales		2.39

25 Analysts have issued a CSPC Pharmaceutical Group Limited forecast for earnings per share. The average CSPC Pharmaceutical Group Limited EPS is

unlock

. This is

unlock

than earnings per share in the financial year 2025. The highest EPS forecast is

unlock

, the lowest is

unlock

This results in the following potential growth metrics and future valuations:

2025	HK$0.40	6.98%
2026	HK$0.83 107.50% unlock
2027	HK$0.60 27.71% unlock
2028	HK$0.61 1.67% unlock
2029	HK$0.52 14.75% unlock
2030	HK$0.55 5.77% unlock
2031	HK$0.58 5.45% unlock
2032	HK$0.60 3.45% unlock

Current	27.06	33.34%
2026	10.71 60.42% unlock
2027	14.94 39.50% unlock
2028	14.54 2.68% unlock

Based on analysts' sales estimates for 2026, the CSPC Pharmaceutical Group Limited stock is valued at an EV/Sales of

unlock

and an P/S ratio of

unlock

This results in the following potential growth metrics and future valuations:

Current	3.09	4.75%
2026	2.39 22.53% unlock
2027	2.56 7.03% unlock
2028	2.44 4.68% unlock
2029	2.15 12.05% unlock
2030	2.02 5.79% unlock
2031	1.89 6.66% unlock
2032	1.77 6.47% unlock
2033	1.66 6.12% unlock

Current	3.42	5.73%
2026	2.64 22.58% unlock
2027	2.83 7.04% unlock
2028	2.70 4.68% unlock
2029	2.37 12.04% unlock
2030	2.24 5.79% unlock
2031	2.09 6.65% unlock
2032	1.95 6.47% unlock
2033	1.83 6.12% unlock

CSPC Pharmaceutical Group Limited...

Discover more stocks with a high price target

NIO ADR 100.10%

Alibaba Group Holding Ltd 68.75%

Infineon 65.25%

Tencent Holdings Ltd. 63.10%

Rheinmetall 61.30%

TUI 56.70%

Adyen 53.16%

Siemens Energy 49.14%

Adidas 46.64%

Uber Technologies 46.13%

BYD 40.95%

NVIDIA 37.67%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now